Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
Marie Dilly-FeldisNathalie AladjidiJohn K RefaitMarie ParrensStéphane DucassouAnne RullierPublished in: Pediatric blood & cancer (2019)
The identical labeling profiles of the cured and relapsed/refractory patients suggest that comparable responses to inhibitors of the PD1/PDL1 immunological checkpoints could be expected in patients undergoing first-, second-, or third-line therapy.
Keyphrases
- patients undergoing
- end stage renal disease
- newly diagnosed
- hodgkin lymphoma
- ejection fraction
- poor prognosis
- chronic kidney disease
- acute lymphoblastic leukemia
- acute myeloid leukemia
- young adults
- peritoneal dialysis
- prognostic factors
- diffuse large b cell lymphoma
- stem cells
- long non coding rna
- patient reported outcomes
- smoking cessation